FDA approves Regeneron’s hearing loss gene therapy
Summary
Otarmeni, now cleared to treat a rare, inherited kind of hearing loss, is the first gene therapy cleared under the FDA’s “national priority” voucher progr...
Description
Otarmeni, now cleared to treat a rare, inherited kind of hearing loss, is the first gene therapy cleared under the FDA’s “national priority” voucher progr...
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source